Pharmacogenetics of Parkinson’s Disease – Through Mechanisms of Drug Actions
Marek Drozdzik, Monika Bialecka and Mateusz Kurzawski
Pages 568-577 (10)
In the last years due to development of molecular methods a substantial progress in understanding of genetic
associations with drug effects in many clinical disciplines has been observed. The efforts to define the role of genetic polymorphisms
in optimizing pharmacotherapy of Parkinson’s disease (PD) were also undertaken. So far, some promising
genetic loci for PD treatment were determined. In the review pharmacogenetic aspects of levodopa, dopamine agonists
and COMT inhibitors are discussed.
Parkinson's disease, Pharmacogenetics, Genetic polymorphism.
Department of Pharmacology, Pomeranian Medical University, Powstancow Wlkp. 72 70-111 Szczecin, Poland.